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Abstract High-quality, safe, and effective biosimilars
have the potential to increase access to biological therapies
worldwide and to reduce cancer care costs. The European
Medicines Agency (EMA) was the first regulatory
authority to establish legislative procedures for the
approval of biosimilars when they published their guide-
lines on similar biological medicinal products in 2005.
Biosimilar epoetins were first approved in 2007, and a
wealth of data has been collected over the last decade. Two
biosimilar epoetins (under five commercial names) have
been approved by the EMA so far. The availability of
epoetin biosimilars generated discussion among the
oncology community regarding prescribing these products,
their efficacy, and their safety. These agents are approved
only if they are shown in extensive analytical and clinical
testing to have comparable quality, safety, and efficacy to
the reference medicine, and real-world studies provide
further data that biosimilar epoetins are an effective and
well-tolerated option for the treatment of chemotherapy-
induced anemia in patients with cancer. Other countries
have adopted similar regulatory pathways to those in
Europe and have approved epoetin biosimilars. The now
extensive European experience with biosimilar epoetins
should reassure regulators from other territories.
Key Points
Biosimilar epoetin alfas have now been available in
Europe for a decade. The availability of biosimilars
provides an opportunity to contain spending on
expensive medications while improving treatment
access for patients.
Based on the now extensive experience with
biosimilar epoetins in Europe, healthcare
professionals and their patients should be reassured
about the therapeutic equivalence of biosimilar
epoetins.
1 Introduction
The high price of biological agents contributes to the huge
healthcare burden associated with cancer treatment [1, 2].
However, expiration of patents for biological agents,
including first-generation epoetins, provides an opportunity
to develop and produce similar biological medicines, ter-
med biosimilars [1]. High-quality, safe, and effective
biosimilars have the potential to increase access to bio-
logical therapies worldwide and to reduce cancer care costs
[3].
The European Medicines Agency (EMA) was the first
regulatory authority to establish legislative procedures for
& Andriy Krendyukov
andriy.krendyukov@sandoz.com
1 Institut Multidisciplinaire d’Oncologie, Clinique de Genolier,
Genolier, Switzerland
2 Hematology/Nephrology, Sandoz Biopharmaceuticals,
HEXAL AG, Industriestr. 25, 83607 Holzkirchen, Germany
3 Sandoz Biopharmaceuticals, Sandoz International GmbH,
Kundl, Austria
4 Department of Hematology-Oncology, Hospital Clı´nic de
Barcelona, University of Barcelona, Barcelona, Spain
BioDrugs
https://doi.org/10.1007/s40259-018-0262-9
the approval of biosimilars when they published their
guidelines on similar biological medicinal products in 2005
[4]. The EMA regulatory pathway for the approval of
biosimilars is based on demonstrating comparable quality,
safety, and efficacy with no clinically meaningful differ-
ences to the originator (reference) medicine [4]. In addition
to general guidelines on biosimilars, the EMA have issued
guidelines for specific product classes, including biosimilar
epoetins [5].
Chemotherapy-induced anemia (CIA) is a significant
complication in cancer patients; however, erythropoiesis-
stimulating agents (ESAs) such as epoetin alfa have been
demonstrated to increase hemoglobin levels, reduce the
need for transfusions, and improve quality of life in anemic
patients with solid or hematologic malignancies receiving
platinum or non-platinum chemotherapy [6].
Biosimilar epoetins were first approved in Europe in
2007, and a wealth of data has been collected over the last
decade. Two biosimilar epoetins (under five brand names)
have been approved by the EMA. HX575 is a biosimilar
version of Eprex/Erypo (Janssen-Cilag, High Wycombe,
UK), and in 2007, it became the first biosimilar epoetin to
be approved in Europe. HX575 has the same international
non-proprietary name (INN) as epoetin alfa and is mar-
keted as Binocrit (Sandoz GmbH, Kundl, Austria), Epo-
etin alfa HEXAL (Hexal, Holzkirchen, Germany), and
Abseamed (Medice Arzneimittel, Iserlohn, Germany).
SB309 is a biosimilar epoetin that also has Eprex/Erypo
as its reference medicine, but the manufacturer applied for
the INN epoetin zeta. It is marketed as Retacrit (Hospira
UK Limited, Maidenhead, UK) and Silapo (STADA, Bad
Vilbel, Germany). The availability of epoetin biosimilars
generated discussion among the oncology community
regarding possible concerns about prescribing these prod-
ucts. This review will discuss initial concerns raised about
epoetin biosimilars, describe data gained on their use in
Europe over the past 10 years, and discuss what can be
learned as epoetin biosimilars are evaluated for use in other
markets.
2 Initial Concerns About the Introduction
of Biosimilar Epoetins
2.1 Low-Quality Medicines
One of the initial concerns raised about biosimilar
medicines was that they may be of low quality, compared
with the licensed reference medicine [7]. However, the
same Good Manufacturing Practices (GMPs) apply equally
to biosimilars and their reference medicines. In addition,
extensive characterization of the biosimilar is a key
requirement of the regulatory process. Characterization
generally consists of analyses of primary (i.e., amino acid
sequence), secondary, tertiary, and quaternary structures,
including aggregation, post-translational modification (e.g.,
glycosylation, phosphorylation, and deamidation), chemi-
cal modification, and biological activities [8].
Biosimilar manufacturers are able to take advantage of
technological improvements and use state-of-the-art sys-
tems to produce and purify biosimilar proteins. This con-
trasts with manufacturers of reference medicines, who may
be locked in to older technologies due to the financial and
regulatory impact of making changes to their methods [9].
Indeed, studies have shown the quality of biosimilar epo-
etins and the reference medicine to be equally as good or,
in some cases, they have shown the biosimilars to have
lower levels of certain impurities [10, 11]. It should be
noted, however, that assured quality may not be the case
for some epoetins available on the market worldwide, in
particular, ‘‘intended copy’’ biological epoetins manufac-
tured in countries where rigorous regulations and stan-
dardized manufacturing processes may not be in place or
adhered to [12].
2.2 Lack of Similarity with the Reference Medicine
Biologics are derived from living cells or organisms and
consist of relatively large and often highly complex
molecular entities. There were initial concerns in some
quarters that biosimilars would not be sufficiently similar
to the reference medicine. A small degree of controlled
variability is common with all biologics, and batches of the
same medicine (whether a reference or biosimilar medi-
cine) are never identical to each other [7]. Due to
unavoidable differences in manufacturing processes, a
biosimilar and the reference medicine will also not be
completely identical (for example, in the levels of minor
impurities or variation in the glycan profile); however,
extensive characterization and comparison, as detailed
above, should ensure that any microheterogeneity does not
impact on the clinical performance of the biosimilar. In
addition, it is a clear requirement that the protein backbone
(i.e., amino acid sequence) of a biosimilar must be identical
to the reference medicine.
Some small differences in non-critical parameters
between biosimilars and the reference epoetin have been
demonstrated. For example, high mannose-6-phopshate
structures have been detected in HX575 at higher levels
than in reference epoetin alfa [13]. For SB309, the protein
contains more glycoforms without an O-glycan chain than
the reference epoetin alfa; however, there appear to be no
clinical consequences [14]. Neither of these quality attri-
butes is critical to clinical efficacy, safety, or immuno-
genicity, as confirmed in the clinical development
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programs and follow-up studies for each biosimilar that
confirmed similarity with the reference medicine (Fig. 1).
2.3 Extrapolation of Indications
Concerns have been expressed about using biosimilars in
indications or in patient populations that are approved for
the reference medicine but have not been formally inves-
tigated during the clinical development of the biosimilar
[7, 15]; this is known as extrapolation. Extrapolation is an
important element of the biosimilarity concept. Several
professional medical societies have discouraged use of
biosimilars in extrapolated indications [16–21]. However,
from a scientific and regulatory perspective, the active
substance of the biosimilar is considered to be just another
version of the active substance of the reference medicine
[15].
The scientific principles behind extrapolation of data are
not new for biosimilars; they also apply to the comparison
of approved products before/after a change in the manu-
facturing process [15]. When biosimilar comparability has
been demonstrated, extrapolation to other indications of the
reference medicine could be acceptable, but needs to be
scientifically justified and considered in light of all avail-
able (analytical, nonclinical, and clinical) data [15]. Reg-
ulators might require additional data to be provided in
some instances: the active substance of the reference
medicine interacts with several receptors that may have a
different impact in the tested and non-tested therapeutic
indications; the active substance itself has more than one
active site and the sites may have a different impact in
different therapeutic indications; or the studied therapeutic
indication is not sensitive enough to detect differences in
all relevant aspects of efficacy and safety. Since clinical
studies are usually less sensitive for detecting potential
differences between the biosimilar and the reference
medicine, the additional data would preferably include
pharmacodynamic parameters and/or specific functional
assays that reflect the pharmacologic action(s) of the
molecule [15]. For epoetin, the mechanism of action is the
same for all currently approved indications, and there is
only one known epoetin receptor; therefore, EMA states
that ‘demonstration of efficacy and safety in renal anemia
will allow extrapolation to other indications of the refer-
ence medicine with the same route of administration’ [5].
2.4 Concerns About Clinical Safety, Including
Immunogenicity
Immunogenicity is a safety concern for all biological
medicines. Antibodies generated against exogenously
administered erythropoietin may, in rare cases, have a
Fig. 1 Clinical development
programs of European
biosimilar epoetins. CIA
chemotherapy-induced anemia,
CKD chronic kidney disease,
HD hemodialysis, IV
intravenous, PD
pharmacodynamic, PK
pharmacokinetic, SC
subcutaneous
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neutralizing effect and lead to pure red cell aplasia (PRCA)
[7]. This is usually more of a concern in patients with
chronic kidney disease (CKD) than in patients with CIA
[2]. Analytical or animal data cannot predict immune
responses in humans; human safety data are therefore
required for EMA approval of all biosimilar products,
including biosimilar epoetins [7]. This involves at least
12 months of comparative immunogenicity results, using a
validated and highly sensitive assay for anti-epoetin anti-
body detection [5].
None of the studies in the clinical program with HX575
or SB309 administered intravenously (IV) reported the
presence of neutralizing anti-erythropoietin antibodies or
any signs or symptoms consistent with immune-mediated
PRCA [13, 22]. The subcutaneous (SC) route of adminis-
tration is usually more immunogenic than the IV route [5].
Indeed, two patients with CKD-related anemia developed
neutralizing anti-erythropoietin antibodies following SC
administration of HX575 in an investigational randomized
clinical trial [23]. A root-cause analysis suggested that
tungsten contamination of prefilled syringes may have
increased the immunogenicity of a small number of study
drug batches [24]. A change in the manufacturing process
was implemented (introduction of low-tungsten syringes)
and, following the completion of a clinical study, HX575
was approved by the EMA for SC administration in CKD
patients in March 2016 [25]. Considering post-approval
data for EU-authorized biosimilar epoetins, a patient with
CKD-related anemia receiving SC epoetin zeta in Italy was
reported to have developed immune-mediated PRCA [26].
In contrast to EMA-approved and regulated biosimilar
epoetins, confirmed cases of PRCA have been reported in
23 Thai patients receiving regionally manufactured copy
epoetins not approved in Europe [27]. This higher-than-
expected rate corresponds to an estimated frequency of one
PRCA case for every 2608 patients using epoetin.
Thrombotic complications may also be a concern with
epoetins in patients with cancer, particularly if there is an
exaggerated pharmacodynamic response [5]. The safety
trial with SB309 was conducted in patients with CIA to
provide information on the incidence of clinically signifi-
cant thrombotic events, which was shown to be similar to
or lower than the published rate for epoetin-treated cancer
patients [22].
To further ensure safety, post-marketing, and risk
management, pharmacovigilance plans must be submitted
for biosimilar epoetins in Europe [28]. In a post-marketing
study of IV HX575, involving more than 1700 patients
with anemia due to CKD, no subjects developed anti-ery-
thropoietin antibodies [29]. Data from the ORHEO (place
of biOsimilaRs in the therapeutic management of anemia
secondary to chemotherapy in HaEmatology and Oncol-
ogy) observational study (n = 2333) in France, conducted
primarily in patients using SB309, indicate a post-mar-
keting safety profile consistent with the reference epoetin
alfa [30, 31]. More recently, a population-based observa-
tional cohort study of more than 13,000 patients reported
no difference in safety outcomes between treatment with
biosimilar epoetins, reference epoetin alfa, and other ESAs
[32]. Thus, for those initially concerned about the safety of
epoetin biosimilars, reassurance is provided by data now
accumulated, which demonstrate that there have been no
specific safety signals after 10 years of clinical usage in
Europe.
The current estimated exposure to HX575/Binocrit
is[200 million patient-days; around 4000 patients have
been included in clinical studies with Binocrit, and the
product is launched in[40 countries. For SB309/Re-
tacrit, the total estimated population exposure (in the
oncology and nephrology indication) between December
2007 and November 2013 was 54,554,947 patient-days,
based on post-marketing sales, with over 35,000,000
patient-days’ experience in the oncology indication [31].
There have also been some discussions on potential
safety risks associated with switching to and from
biosimilar products [33]. A retrospective drug utilization
study conducted in Italy quantified the occurrence of
switching between different epoetins [34]. When switched
from the reference epoetin alfa, 62% of patients received
another patented epoetin alfa (darbepoetin alfa, epoetin
beta, or methoxypolyethyleneglycol-epoetin beta) and 32%
received a biosimilar epoetin alfa. Patients who initially
used a biosimilar epoetin alfa were mostly switched to the
reference epoetin alfa (57.5%), with 27.5% switched to
another patented epoetin and 15% to another biosimilar
epoetin alfa [34]. The probability of switching was asso-
ciated with the duration of treatment: about 15% of users
switched within 12 months and almost 25% within 2 years
of observation. Switching was not restricted to the
replacement of reference epoetins with biosimilar epoetins,
but also extended to products that have not been directly
compared in clinical studies. The authors concluded that
the level of switching may provide reassurance to physi-
cians when taken together with other sources of compara-
tive evidence [34]. The decision to switch epoetins is
usually due to a hospital or hemodialysis unit changing all
of its patients from one erythropoietin to another [33].
Switching between epoetins is probably much less likely in
the setting of CIA than other indications (such as CKD-
related anemia), as the duration of epoetin therapy is typ-
ically much shorter in the oncology setting. A review of
data from clinical trials, pharmacovigilance databases, and
an overview of the literature found no evidence to suggest
that switching to and from different biopharmaceuticals
(including biosimilars) leads to safety concerns [33]. A
retrospective analysis of 149 adult hemodialysis patients
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receiving stable ESA doses has reported a dose penalty
when switching from the reference to a biosimilar epoetin
alfa [35]. However, this report of a dose penalty is contrary
to other published data. These include a large post-approval
study of IV HX575 in patients (n = 1695) with CKD and a
population-based analysis of real-world data from ambu-
latory patients (n = 6117) with CKD undergoing mainte-
nance hemodialysis [29, 36].
3 Looking Beyond the European Experience
In the European Union (EU), the first biosimilar product
was approved in 2006 and the first biosimilar epoetin in
2007 [37]. Since then, many countries and regions have
developed regulatory and approval processes based on the
EMA’s approach. For example, biosimilar epoetins were
first approved in Australia in 2010 and in New Zealand in
2013 [28]. However, it is only relatively recently that the
first biosimilar was approved in the United States (US).
The US enacted the Biologics Price Competition and
Innovation Act in 2010 as part of the Patient Protection
and Affordable Care Act, to clarify and expedite the
approval process for biosimilar agents [37]. US Food and
Drug Administration (FDA) guidance on biosimilars was
slow to emerge due to debates by stakeholders over how
stringent the standards for new biosimilar approvals should
be and whether approved biosimilars should be used
interchangeably with reference medicines [38]; final
guidelines on scientific and quality considerations in
demonstrating biosimilarity were issued by the FDA in
2015 [39]. Unlike in Europe, the FDA pathway includes a
regulatory designation on interchangeability, which, in the
US, refers to the ability to automatically substitute a
medicine at the pharmacy level. This requires additional
data over and above what is needed for biosimilarity alone;
the sponsor must demonstrate that, if administered more
than once to an individual, the risk in terms of safety or
diminished efficacy of switching between the biosimilar
and the reference medicine is not greater than the risk of
using the reference medicine alone [39]. The EMA and
Australian authorities do not provide an interchangeable
recommendation when approving a biosimilar. However, in
a recent article authored by employees of several national
regulatory agencies in Europe, the authors state their
opinion that EU-approved biosimilars are considered
medically interchangeable; this refers, in the EU, to the
practice of changing one medicine for another that is
expected to achieve the same clinical effect in a given
clinical setting and in any patient, with the agreement of
the prescriber [40]. The authors argue that attempts to
provide data on a lack of switch-related changes in safety
and efficacy with specific interchangeability studies would
be demanding, and unlikely to provide definitive answers
[40]; instead, state-of-the-art demonstration of biosimilar-
ity plus heightened post-marketing surveillance should be a
sufficient and realistic approach to ensuring interchange-
ability with supervision from prescribers. The authors
conclude that EU-licensed biosimilars are interchangeable
‘if the patient is clinically monitored, will receive the
necessary information, and, if needed, training on the
administration of the new product’ [40]. In Europe, deci-
sions on automatic substitution between a biological ref-
erence medicine and its biosimilar are made at the level of
individual countries [5, 28].
Other additional areas of debate in the US relate to
naming, payment, and pharmacovigilance [38]. Under the
FDA regulatory pathway, the first biosimilar product, a
granulocyte colony-stimulating factor, Zarzio (Zarxio,
filgrastim-sndz; Hexal AG, Germany), was approved in the
US in March 2015 for all the same indications as the ref-
erence medicine, Neupogen [41]. Unlike in Europe, the
FDA approved filgrastim-sndz without a requirement for
post-marketing studies, and a lack of post-approval moni-
toring may be a concern to some healthcare professionals
in the US [38]. Therefore, the provision of adequate pro-
fessional and patient education regarding the equivalence
of biosimilars is likely to be an important factor in
acceptance [38]. In addition, the European experience
should provide reassurance and the likely economic bene-
fits may provide incentives for adoption. The expiry of
patents in 2014 has potentially opened the US market to
biosimilar epoetins; indeed, the FDA’s Oncology Drugs
Advisory Committee has recently recommended approval
of a proposed biosimilar epoetin alfa [42]. In another recent
development in the US, the FDA determined that the ESA
Risk Evaluation and Mitigation Strategy (which was lim-
ited to the use of ESAs to treat patients with anemia due to
associated myelosuppressive chemotherapy) was no longer
necessary to ensure that the benefits outweigh the risks of
shortened overall survival and/or increased risk of tumor
progression or recurrence in patients with cancer [43].
4 Summary
Biosimilars, including biosimilar epoetin alfas, have now
been available in Europe for a decade. The availability of
biosimilars offers affordable, high-quality, effective alter-
native treatments, and may help contain healthcare bud-
gets, while improving treatment access for patients. These
agents are approved only if they are shown in extensive
analytical and clinical testing to have comparable quality,
safety, and efficacy to the reference medicine, and real-
world studies provide further data that biosimilar epoetins
are an effective and well-tolerated option for the treatment
Epoetin Biosimilars in Chemotherapy-Related Anemia
of anemia. Other countries have adopted similar regulatory
pathways to those in Europe and have approved epoetin
biosimilars; however, expansion into the US market is still
awaited. The now extensive European experience will
reassure healthcare professionals about the therapeutic
equivalence of biosimilar epoetins, and, together with
comprehensive education, may help drive acceptance
among payers and healthcare professionals if these agents
gain approval.
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